Cargando…

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

Chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma are indolent B-cell lymphoproliferative disorders that mainly affect an older population. Although the majority of patients in need of treatment derive significant benefit from conventional chemotherapeutic agents as w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Madanat, Yazan F, Smith, Mitchell R, Almasan, Alexandru, Hill, Brian T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929980/ https://www.ncbi.nlm.nih.gov/pubmed/27375364 http://dx.doi.org/10.2147/BLCTT.S73530

Ejemplares similares

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
por: Cuneo, Antonio, et al.
Publicado: (2018)

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
por: Kost, Sara E. F., et al.
Publicado: (2019)

Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma
por: Yoshino, Tadashi, et al.
Publicado: (2020)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018)

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
por: Falchi, Lorenzo, et al.
Publicado: (2016)

Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells
por: Hock, Barry D., et al.
Publicado: (2017)

Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells
por: Modi, Prexy, et al.
Publicado: (2017)

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
por: Sharman, Jeff P., et al.
Publicado: (2019)

Disseminated cryptococcal disease during treatment with idelalisib and corticosteroids for follicular lymphoma
por: Hengeveld, Paul J, et al.
Publicado: (2020)

Various inclusions in chronic lymphocytic leukemia/small lymphocytic lymphoma
por: Galiacho, Verónica Roldán, et al.
Publicado: (2022)

Cardiac Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
por: Robak, Tadeusz, et al.
Publicado: (2022)

Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential
por: Barrientos, Jacqueline C
Publicado: (2016)

Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia with Chromothripsis in an Old Woman
por: Tan, Li, et al.
Publicado: (2015)

Leishmania in a Patient with Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
por: Nicolas, Gregory, et al.
Publicado: (2018)

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
por: Schieber, Michael, et al.
Publicado: (2019)

Pathology of Seminoma Coinciding With Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
por: Bui, Katherine M, et al.
Publicado: (2021)

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
por: Kreuzer, Karl-Anton, et al.
Publicado: (2019)

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
por: Burke, Russell T, et al.
Publicado: (2014)

Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
por: Schetelig, Johannes, et al.
Publicado: (2020)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia
por: Primo, Daniel, et al.
Publicado: (2018)

Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group
por: von Tresckow, Julia, et al.
Publicado: (2023)

Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
por: Schetelig, Johannes, et al.
Publicado: (2021)

Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
por: Sellner, Leopold, et al.
Publicado: (2020)

Merkel cell carcinoma mimicking transformed chronic lymphocytic leukemia/small lymphocytic lymphoma
por: Bah, Ismael, et al.
Publicado: (2019)

Intestinal Infiltration of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Found on Screening Colonoscopy
por: Aje, Kent T, et al.
Publicado: (2022)

An unusual presentation of chronic lymphocytic leukemia/small lymphocytic lymphoma on mammography: Case report
por: Mohamed, Anas, et al.
Publicado: (2021)

Toxic Encephalopathy After Relapsed Indolent Non-Hodgkin’s Lymphoma Following Abrupt Discontinuation of Idelalisib (ZYDELIG®)
por: Shenouda, Mina, et al.
Publicado: (2019)

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial
por: Ghia, Paolo, et al.
Publicado: (2020)

Coexistence of T-Large Granular Lymphocyte Leukemia and Peripheral T Cell Lymphoma-NOS with Indolent Behavior
por: Guarnera, Luca, et al.
Publicado: (2022)

Sweet Syndrome in a Patient with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Curious Lymphocyte/Neutrophil Fluctuations
por: Usul Afşar, Çiğdem, et al.
Publicado: (2013)

New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals
por: Stancu, Andreea Lucia, et al.
Publicado: (2014)

Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study
por: Casadei, Beatrice, et al.
Publicado: (2022)

Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
por: Sellner, Leopold, et al.
Publicado: (2021)

CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia
por: Montraveta, Arnau, et al.
Publicado: (2015)

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
por: Rigolin, Gian Matteo, et al.
Publicado: (2021)

Case report: Chronic lymphocytic leukemia/small lymphocytic lymphoma and monomorphic epitheliotropic intestinal T-cell lymphoma: A composite lymphoma
por: Zhang, Bing, et al.
Publicado: (2022)

A Rare Case of Composite Dural Extranodal Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
por: Bustoros, Mark, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_avslmtp0vcjqg3t70vca5setl6